Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: graybug.vision
Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to "CALC." The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica). About GraybugGraybug is a clinical-stage biopharmaceutical company focused on developing transform
– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) ("Graybug" or the "Company"), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the same period in 2021. Research and development expense for the quarter ended September 30, 2022 was $3.2 million compared to $4.0 million for the same period in 2021. The decrease was primarily due
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Alternatives being explored include the potential for an acquisition, company sale, merger, d
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022. Information about the event is listed below and available on the OIS Retina website. Graybug Pipeline Opportunities in RetinaPresenter: Fred Guerard, PharmD, Chief Executive Officer, Graybug Vision Session: Spotlight on Drug Delivery & Durability Date and Time: Wednesday, July 13, 2022; 1:32 p.m. – 1:39 p.m. ETLocation:
BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this process, the Company will explore the potential for an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions. As of March 31, 2022, the company's cash, cash equivalents, and short-term investments totaled $55.3 million. Graybug has retained Piper Sa
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision, will present an update on the clinical development plan for GB-102 in wet age-related macular degeneration, and will be part of a subsequent panel discussion at the upcoming Clinical Trials at the Summit Meeting, to be held in person at the Hyatt Regency Lake Tahoe in Nevada, as well as virtually, on May 21, 2022. Clinical Trials at the Summit brings together a diverse group of experts from around th
BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the quarter ended March 31, 2022. Recent Corporate Developments Committed to advancing GB-102 into additional wet-AMD clinical trial — enhanced formulation of GB-102, designed to reduce or eliminate microparticle dispersion, has been developed for an additional Phase 2 trial to further evaluate safety, efficacy and durability demonstrated in the ALTISSIMO trial.Expanded pipeline w
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022. Information is listed below and available on the ARVO website. In Vitro and In Vivo Characterizations of GB-401, a Sustained-Release Intravitreal Implant Containing a Beta-Adrenergic Antagonist Prodrug fo
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) ("Graybug" or the "Company"), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the same period in 2021. Research and development expense for the quarter ended September 30, 2022 was $3.2 million compared to $4.0 million for the same period in 2021. The decrease was primarily due
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Alternatives being explored include the potential for an acquisition, company sale, merger, d
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter of 2023New programs for Retinitis Pigmentosa and Geographic AtrophyCurrent cash expected to fund planned operations into fourth quarter of 2023Graybug to host virtual Investor R&D Day today, March 30, 2022, beginning at 11 a.m. ET BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today an
Phase 2/3 ReMEDy2 Trial in AIS for Stroke Outcomes and Stroke Recurrence on Track for Initiation Summer 2021 Positive REDUX Phase 2 Interim Data Announced for CKD: IgA Nephropathy Data Indicate Statistically & Clinically Significant 33% Reduction in Albuminuria (UACR). Board of Directors Strengthened with Election of Two Pharma Industry Veterans Conference Call and Webcast August 12 at 8:00 am Eastern Time / 7:00 am Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended June 3
REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and six months ended June 30, 2021. Recent Corporate Developments Completed six-month extended observation period of ALTISSIMO Phase 2b trial in wet AMD— 28 of the 50 patients who completed their Month 12 visit were eligible and agreed to continue masked clinical monitoring until the point at which they required additional supportive therapy, up t
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
4 - CalciMedica, Inc. (0001534133) (Issuer)
SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)
SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)
SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
SC 13G - CalciMedica, Inc. (0001534133) (Subject)
SC 13G - CalciMedica, Inc. (0001534133) (Subject)
SC 13G - CalciMedica, Inc. (0001534133) (Subject)
SC 13G - CalciMedica, Inc. (0001534133) (Subject)
SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
SVB Leerink downgraded Graybug Vision from Outperform to Market Perform and set a new price target of $5.00 from $23.00 previously
Needham downgraded Graybug Vision from Buy to Hold
SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously
Piper Sandler resumed coverage of Graybug Vision with a rating of Neutral and set a new price target of $10.00 from $27.00 previously
Wedbush resumed coverage of Graybug Vision with a rating of Neutral and set a new price target of $8.00 from $41.00 previously
Wedbush downgraded Graybug Vision from Outperform to Neutral and set a new price target of $8.00 from $41.00 previously
Wedbush downgraded Graybug Vision from Outperform to Neutral
SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously
Piper Sandler downgraded Graybug Vision from Overweight to Neutral and set a new price target of $10.00 from $27.00 previously
8-K - CalciMedica, Inc. (0001534133) (Filer)
EFFECT - CalciMedica, Inc. (0001534133) (Filer)
S-3 - CalciMedica, Inc. (0001534133) (Filer)
8-K/A - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
10-Q - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
8-K - CalciMedica, Inc. (0001534133) (Filer)
EFFECT - CalciMedica, Inc. (0001534133) (Filer)
S-3 - CalciMedica, Inc. (0001534133) (Filer)
Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car
BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022. Dr. Sauer will serve as a member of the Nomination and Corporate Governance Committee of the Board. He will also chair the Science and Innovation Committee, the purpose of which is to advise the Board on the company's research and development as well as clinical manufacturing and control strategies. Dr. Sauer succeeds Gerald Cagle, PhD, who is retiring from the Graybug Bo
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of Bettina Maunz as Chief People Officer. In addition to building and leading the human resources function for Graybug Vision, Ms. Maunz will serve as Head of Communications and be a member of the company’s executive team. “We are delighted for Bettina to join Graybug as Chief People Officer. Her leadership, culture and communications experience will be important assets to our team,” said Frederic Guera